ストックスクリーナーアプリを入手
25.72
0.47%
0.12
前日終値:
$25.60
開ける：
$25.62
24時間の取引高:
29.42M
Relative Volume:
0.78
時価総額：
$145.76B
収益：
$63.63B
当期純損益:
$8.03B
株価収益率:
18.24
EPS:
1.41
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-3.78%
1か月 パフォーマンス:
+0.74%
6か月 パフォーマンス:
-12.13%
1年 パフォーマンス:
-8.57%
1日の値動き範囲:
$25.50
$25.76
1週間の範囲:
$25.50
$27.24
52週間の値動き範囲:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.72 | 145.76B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
813.48 | 730.64B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
211.77 | 373.85B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.81 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
77.15 | 342.47B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
94.57 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Down 93%, Is It Finally Time to Buy Moderna? - The Motley Fool
PTAB Explains Ax Of Moderna Vaccine Patents In Pfizer Case - Law360
10 Most Undervalued S&P 500 Stocks to Buy Now - Insider Monkey
Sumitomo Pharma, Pfizer Target Two Copies of Orgovyx Cancer Drug - Bloomberg Law
Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits - Simply Wall St
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J - Zacks Investment Research
Should You Buy Pfizer Stock At $26? - Forbes
Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again - Citeline News & Insights
Basilea Gets Milestone Payment from Pfizer for Antifungal Sales -March 14, 2025 at 03:49 am EDT - Marketscreener.com
Pfizer (NYSE:PFE) Shares Unloaded Rep. Julie Johnson - Defense World
Guggenheim Reaffirms Buy Rating for Pfizer (NYSE:PFE) - Defense World
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (CORRECTED) - Benzinga
Pfizer Says Chairman & CEO Albert Bourla's 2024 Total Compensation Was $24.6 Mln- SEC Filing - Marketscreener.com
Pfizer Looks Back at 2024 in the Annual Review - Pfizer
Form DEF 14A PFIZER INC For: Apr 24 - StreetInsider.com
White House withdraws vaccine opponent Weldon for CDC director -March 13, 2025 at 12:56 pm EDT - Marketscreener.com
May 2nd Options Now Available For Pfizer (PFE) - Nasdaq
Zai Lab says Pfizer drug Tivdak won China review (ZLAB:NASDAQ) - Seeking Alpha
Womens Health Market Is Booming Worldwide 2025-2032 | Pfizer - openPR
Pfizer sells park land to Portage for $1, deems property was 'surplus' - wwmtarc
Is Pfizer Inc. (PFE) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Shareholders Will Be Pleased With The Quality of Pfizer's (NYSE:PFE) Earnings - Yahoo Finance
Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart
Transthyretin Amyloid Cardiomyopathy Treatment Market Is Booming Worldwide 2025-2032: Pfizer Inc., - EIN News
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
A Snapshot Of What Pfizer's Doing With Teleoperated Robots - BioProcess Online
11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey
Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III - Citeline News & Insights
Sector Update: Health Care Stocks Lower in Late Afternoon Trading -March 11, 2025 at 04:05 pm EDT - Marketscreener.com
Looking At Pfizer's Recent Unusual Options Activity - Benzinga
Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant - Simply Wall St
Pfizer stock, Arvinas stock slip on breast cancer data (PFE:NYSE) - Seeking Alpha
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Benzinga
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients - Yahoo Finance
Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results - Reuters.com
mRNA Cancer Therapeutics Patent Landscape Report and - GlobeNewswire
Injectable Drugs Market Detailed In New Research Report 2025 | Pfizer Inc., Teva Pharmaceutical Industries - EIN News
Arvinas and Pfizer Announce Positive Phase 3 Trial Results - TipRanks
Pfizer: Undervalued Safe Haven In Risk-Off Market (NYSE:PFE) - Seeking Alpha
Pfizer's new drug data in breast cancer draws muted response - pharmaphorum
Pfizer (PFE) Breast Cancer Drug Vepdegestrant Posts Mixed Results in Key Trial - Bloomberg
Pfizer, Arvinas post mixed late-stage breast cancer data for closely watched PROTAC drug - PharmaLive
Pfizer: encouraging data in breast cancer -March 11, 2025 at 08:04 am EDT - Marketscreener.com
Pfizer's breast cancer drug Vepdegestrant posts mixed results in key trial - Business Standard
Atrial Fibrillation Market to Witness Remarkable Growth with Pfizer Inc., Boehringer Ingelheim GmbH - openPR
Migraine Therapeutic Market Is Booming Worldwide 2025-2032 | - openPR
Arvinas, Pfizer Report Positive Topline Data From Phase 3 VERITAC-2 Study - Nasdaq
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study -March 11, 2025 at 06:52 am EDT - Marketscreener.com
Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial - Marketscreener.com
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial - GlobeNewswire
First-Ever PROTAC Cancer Drug Hits Major Trial Milestone: What This Means - StockTitan
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
1.69%
大文字化:
|
ボリューム (24 時間):